Who are Atropine/Neostigmine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atropine-neostigmine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Atropine/Neostigmine — Competitive Intelligence Brief

Atropine/Neostigmine (Atropine/Neostigmine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidote combination; anticholinergic + cholinesterase inhibitor. Area: Toxicology / Emergency Medicine.

marketed Antidote combination; anticholinergic + cholinesterase inhibitor Muscarinic acetylcholine receptors (atropine); acetylcholinesterase (neostigmine) Toxicology / Emergency Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Atropine/Neostigmine (Atropine/Neostigmine) — Hadassah Medical Organization. Atropine blocks acetylcholine at muscarinic receptors while neostigmine inhibits acetylcholinesterase, creating opposing effects that together counteract organophosphate or carbamate poisoning.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atropine/Neostigmine TARGET	Atropine/Neostigmine	Hadassah Medical Organization	marketed	Antidote combination; anticholinergic + cholinesterase inhibitor	Muscarinic acetylcholine receptors (atropine); acetylcholinesterase (neostigmine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidote combination; anticholinergic + cholinesterase inhibitor class)

Hadassah Medical Organization · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Atropine/Neostigmine — Competitive Intelligence Brief. https://druglandscape.com/ci/atropine-neostigmine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab